<DOC>
	<DOCNO>NCT02085473</DOCNO>
	<brief_summary>The aim study evaluate pharmacokinetics tolerability tralokinumab deliver different flow rate healthy volunteer .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Pharmacokinetics Tolerability Tralokinumab When Delivered Different Flow Rates Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Key Healthy male female age 1965 year Body mass index 19.030.0 kg/m2 No clinically significant abnormality Vital sign , electrocardiogram ( ECG ) , laboratory parameter within normal range Negative alcohol drug screen Females childbearing potential sexually active nonsterilized male partner must use highly effective contraception Nonsterilized male sexually active female partner childbearing potential must use highly effective contraception Key Concurrent enrollment another clinical study subject receive investigational product Receipt market investigational biologic agent within 4 month 5 halflives prior screen , whichever long Receipt investigational nonbiologic agent within 3 month 5 halflives prior screen , whichever longer Current use regular painmodifying , antidepressant , anxiolytic , hypnotic medication History thrombocytopenia bleed disorder use anticoagulant History immunodeficiency disorder use immunosuppressive medication . History clinically significant infection History cancer Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>